Inovio Pharmaceuticals Inc. has been the darling of investors for more than a decade and has a market cap of more than $11 billion.
Now it looks like Inovios is getting some serious help from an Israeli pharmaceutical company that has made a big push into the market for the generic version of its blockbuster drug, ketamine.
The Kiniysa pharmaceutical company, which is backed by Israeli drug maker INN, will use the Israeli firm’s expertise in the treatment of schizophrenia to develop its ketamine-based drug, Israel’s Elagal, which will be sold under the brand name of “Kiniksi” on the Israeli market.
It will be available as a generic form, which means the drug can be sold without a prescription and will be priced at a lower price than its competitors.
The drug is also being developed with Israeli pharma giant Shire Pharmaceuticals and will enter the Israeli pharmacy market in 2020.
Inovios will take a $400 million injection of cash from Shire, which bought its controlling stake in the company in 2016.
It is unclear if Shire is also financing Inoviol’s drug development or if the Israeli company is investing in its own development.
In a statement, Shire said that the deal was “a very important strategic partnership between the two companies that will provide continued benefits to the entire pharmaceutical industry.”
The Kinisa drug company also has a stake in another Israeli company, Inovion Pharmaceuticals, which also produces ketamine derivatives.
The Israeli company’s drug was the first drug approved by the U.S. Food and Drug Administration (FDA) in the country, and it is currently in clinical trials.
Inovions ketamine drug, which has been approved by regulators in France and Germany, was approved by Japan’s National Institute of Mental Health in March and is expected to be approved by U.K. regulators in early 2020.
A spokesman for INN did not respond to a request for comment on whether the company was supporting Inoviys ketamine efforts.
KiniysA drugmaker that has been developing ketamine drugs for decades, Inoviys is based in Israel.
It makes a ketamine derivative called Kiniya.
Kinisya, which was originally approved by France in 2006, has also been approved in the U!
K., Switzerland and the Umea province in Sweden.
The drug has been used to treat schizophrenia in some patients and has been licensed in Israel and Germany for other ailments.
Kino, a German company that specializes in ketamine and is working on its own ketamine product, has been looking for a new market for its drug for a long time.
The company announced last year that it had secured a deal with a U.N. agency in Israel to develop ketamine to treat the brain injury that killed a man in 2011.KINO plans to manufacture and sell its drug under the Kiniy name and said it will use Israeli expertise to develop the drug.
It said it expects to sell the drug in the $1,000-to-1,500-per-milliliter range and that the price tag is between $1.5 million and $2 million.
Inoviys said it expected to produce KiniYas generic version for the U., U.M., UPA, EU and AU markets in 2020 and will begin selling its generic version to its U.A. patients in 2020, while it works to produce a generic version that can be used by its own patients.
The company said it plans to work with the ULA, which oversees U.C.L.A., to create a unified U.L., UCA and AU distribution network that would enable Inoviis generic drug to be available in the two markets in which it has yet to be tested.
Kinaa, which makes a generic ketamine called Kina, has not announced any details about its deal with INN.
KinosKino has a long history of developing drugs for people with mental illnesses, and the company has been working on a number of new ketamine medications for years.
The new ketamines could help patients who suffer from depression and anxiety as well as add to the company’s already vast ketamine portfolio.
The drugs could also help people with substance use disorders like opioid dependence.
KinskiyKino said in a statement that it expects the UKA to begin selling the drug by 2020 and said its price will be around $500 to $1 and $1 per milliliter.
The product is expected be available on the UO, UPA and AU marketplaces in 2020 as well.
The Kino product was also approved by Swiss regulators for use in the acute treatment of severe agitation, panic attacks and psychotic symptoms.
Kino said the drug has not been shown to improve symptoms of anxiety and depression, but it could help treat those symptoms